ClinicalTrials.Veeva

Menu
C

Chase Medical Research, LLC | Waterbury, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Tirzepatide
LY3298176
Retatrutide
Bapineuzumab
LY3437943
Orforglipron
Insulin icodec
Semaglutide
LY3502970
Finerenone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

34 of 126 total trials
Locations recently updated

A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)

Researchers designed a trial medicine called MK-7262 to lower levels of Lp(a) in the blood. Researchers want to learn about giving MK-7262 with anoth...

Enrolling
Lipoprotein(a)
Drug: Enlicitide
Drug: Placebo for enlicitide

This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.

Enrolling
Acute Migraine
Drug: Placebo
Drug: Elismetrep

The GZPL master protocol will support 2 independent studies, J2A-MC-GZL1 (GZL1) and J2A-MC-GZL2 (GZL2). The purpose of this study is to create a fram...

Active, not recruiting
Hypertension
Drug: Orforglipron
Drug: Placebo

GZL1 is an independent study conducted under the GZPL master protocol. GZL1 will evaluate the efficacy and safety of orforglipron for treatment of hy...

Active, not recruiting
Hypertension
Overweight or Obesity
Drug: Placebo
Drug: Orforglipron

GZL2 is an independent study conducted under the GZPL master protocol. GZL2 study will evaluate the efficacy and safety of orforglipron for treatment...

Active, not recruiting
Hypertension
Drug: Orforglipron
Drug: Placebo

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee oste...

Enrolling
Knee Osteoarthritis (OA)
Obesity
Drug: NNC0487-0111
Drug: Placebo (matched to NNC0487-0111 )

This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The...

Active, not recruiting
Diabetes Mellitus, Type 2
Drug: Semaglutide
Drug: Placebo (semaglutide)

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Eloralintide

The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity o...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: Eloralintide

CKJX839D12302 is a pivotal Phase III study designed to test the hypothesis that treatment with inclisiran sodium 300 milligram (mg) subcutaneous (s.c...

Active, not recruiting
Primary Prevention of Atherosclerotic Cardiovascular Disease
Drug: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Drug: Placebo in 1.5ml

The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabet...

Active, not recruiting
Obesity
Type 2 Diabetes
Drug: Tirzepatide
Drug: Placebo

The GZPT master protocol will support two independent studies, J2A-MC-GZT1 and J2A-MC-GZT2. Each study will see how well and safely orforglipron work...

Enrolling
Osteoarthritis
Drug: Orforglipron
Drug: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The main aim of the study is to assess the effect of RO7204239 in combination with tirzepatide, compared to placebo in combination with tirzepatide,...

Active, not recruiting
Overweight
Obesity
Drug: Tirzepatide
Drug: RO7204239 Matching Placebo

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study...

Active, not recruiting
Type 2 Diabetes Mellitus
Drug: Semaglutide
Drug: Placebo

This is a double-blind, randomized, multicenter, outpatient evaluation of the efficacy, safety, and tolerability of elismetrep, as compared with plac...

Enrolling
Migraine
Drug: Placebo
Drug: Elismetrep

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2...

Active, not recruiting
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: VXA-CoV2-3.3

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Active, not recruiting
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

This study is being done to look at the safety and effect of NNC0487-0111 in people with excess body weight and knee osteoarthritis when compared to...

Enrolling
Overweight
Obesity
Drug: Placebo (matched to NNC0487-0111)
Drug: NNC0487-0111

This open-label extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed the double-blin...

Enrolling
Cardiovascular Disease and Lipoprotein(a)
Drug: Pelacarsen (TQJ230)

Trial sponsors

Lilly logo
Novo Nordisk logo
Pfizer logo
Boehringer Ingelheim logo
Novartis logo
Amgen logo
Bayer logo
Janssen (J&J Innovative Medicine) logo
MannKind logo
Moderna logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems